Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP).
暂无分享,去创建一个
A. Lambeir | I. De Meester | L. Maes | P. Cos | P. Van der Veken | J. Joossens | K. Augustyns | Jonathan D. Cheng | R. Verkerk | Koen Jansen | Leen Heirbaut
[1] S. Diano,et al. Prolyl endopeptidase-deficient mice have reduced synaptic spine density in the CA1 region of the hippocampus, impaired LTP, and spatial learning and memory. , 2013, Cerebral cortex.
[2] J. Lai,et al. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. , 2013, Journal of medicinal chemistry.
[3] P. McKee,et al. Targeting inhibition of fibroblast activation protein-α and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments. , 2013, Neoplasia.
[4] A. Lambeir,et al. Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. , 2013, ACS medicinal chemistry letters.
[5] A. Pandey,et al. Proline editing: a general and practical approach to the synthesis of functionally and structurally diverse peptides. Analysis of steric versus stereoelectronic effects of 4-substituted prolines on conformation within peptides. , 2013, Journal of the American Chemical Society.
[6] K. Kodukula,et al. Comparative analysis of the substrate preferences of two post‐proline cleaving endopeptidases, prolyl oligopeptidase and fibroblast activation protein α , 2012, FEBS letters.
[7] A. Lambeir,et al. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. , 2012, Bioorganic & medicinal chemistry letters.
[8] A. Lambeir,et al. Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. , 2012, Clinica chimica acta; international journal of clinical chemistry.
[9] Xin Chen,et al. Structure-activity relationship studies on isoindoline inhibitors of dipeptidyl peptidases 8 and 9 (DPP8, DPP9): is DPP8-selectivity an attainable goal? , 2011, Journal of medicinal chemistry.
[10] P. McKee,et al. Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2‐antiplasmin , 2011, Journal of thrombosis and haemostasis : JTH.
[11] M. Gorrell,et al. Neuropeptide Y, B‐type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein‐α , 2011, The FEBS journal.
[12] S. Hoerstrup,et al. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata , 2011, European heart journal.
[13] A. Bayat,et al. Increased expression of fibroblast activation protein-alpha in keloid fibroblasts: implications for development of a novel treatment option , 2010, Archives of Dermatological Research.
[14] Xin Chen,et al. Substituted 4-carboxymethylpyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein. , 2010, Journal of medicinal chemistry.
[15] Ri-fang Yang,et al. Facile and efficient synthesis of quinoline-4-carboxylic acids under microwave irradiation , 2010 .
[16] E. Puré,et al. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. , 2009, The Journal of clinical investigation.
[17] N. Senzer,et al. Phase II trial of talabostat and docetaxel in advanced non-small cell lung cancer. , 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).
[18] N. Senzer,et al. Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma , 2009, BMC Cancer.
[19] R. Raines,et al. Origin of the stability conferred upon collagen by fluorination. , 2009, Bioorganic & medicinal chemistry letters.
[20] A. Rowan,et al. Emerging roles of serine proteinases in tissue turnover in arthritis. , 2008, Arthritis and rheumatism.
[21] B. O'connor,et al. Seprase: an overview of an important matrix serine protease. , 2008, Biochimica et biophysica acta.
[22] H. Fukushima,et al. Synthesis and structure-activity relationships of potent 1-(2-substituted-aminoacetyl)-4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. , 2008, Chemical & pharmaceutical bulletin.
[23] Xin Chen,et al. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads. , 2008, Bioorganic & medicinal chemistry letters.
[24] Xin Chen,et al. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 2: isoindoline containing inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[25] M. Pal,et al. Synthesis of (S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile: A key intermediate for dipeptidyl peptidase IV inhibitors , 2008, Beilstein journal of organic chemistry.
[26] M. Tadayyon,et al. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors , 2008, Journal of Pharmacology and Experimental Therapeutics.
[27] P. McKee,et al. Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer , 2007, Cancer biology & therapy.
[28] Xin Chen,et al. Irreversible inhibition of dipeptidyl peptidase 8 by dipeptide-derived diaryl phosphonates. , 2007, Journal of medicinal chemistry.
[29] J. A. García-Horsman,et al. On the role of prolyl oligopeptidase in health and disease , 2007, Neuropeptides.
[30] Adam Shilling,et al. Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists. , 2007, Journal of medicinal chemistry.
[31] W. Fairbrother,et al. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly2‐Pro1‐cleaving specificity , 2006, FEBS letters.
[32] E. Puré,et al. Fibroblast activation protein: a serine protease expressed at the remodeling interface in idiopathic pulmonary fibrosis. , 2006, Human pathology.
[33] B. Cravatt,et al. Fibroblast activation protein alpha is expressed by chondrocytes following a pro-inflammatory stimulus and is elevated in osteoarthritis , 2006, Arthritis research & therapy.
[34] S. Keir,et al. Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft , 2005, Molecular Cancer Therapeutics.
[35] K. Aertgeerts,et al. Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein α* , 2005, Journal of Biological Chemistry.
[36] A. Canutescu,et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth , 2005, Molecular Cancer Therapeutics.
[37] Yan Huang,et al. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. , 2004, Cancer research.
[38] C. Abbott,et al. Fibroblast activation protein: A cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis , 1999, Hepatology.
[39] Ping Chen,et al. A practical method for the preparation of α′-chloroketones of N-carbamate protected-α-aminoacids , 1997 .
[40] J. Healey,et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[41] R. Snow,et al. The efficient synthesis and simple resolution of a prolineboronate ester suitable for enzyme-inhibition studies , 1993 .
[42] L. Old,et al. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[43] J. Glass,et al. Leucylglycinamide Released from Oxytocin by Human Uterine Enzyme , 1971, Science.
[44] G. McCaughan,et al. Fibroblast activation protein and chronic liver disease. , 2008, Frontiers in bioscience : a journal and virtual library.